GSK PLC SP. ADR/2 NEW (GS70) — Capital Reinvestment Ratio
GSK PLC SP. ADR/2 NEW (GS70) has a Capital Reinvestment Ratio of 0.24x as of June 2026, meaning it reinvests 0% of its operating cash flow (€2.69 Billion) in capital expenditures (€653.00 Million). Check how tangible is GSK PLC SP. ADR/2 NEW's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GSK PLC SP. ADR/2 NEW Capital Reinvestment Ratio (2021–2025)
This chart tracks GSK PLC SP. ADR/2 NEW's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see GS70 cash generation efficiency.
Annual Capital Reinvestment Ratio for GSK PLC SP. ADR/2 NEW (2021–2025)
Year-by-year Capital Reinvestment Ratio for GSK PLC SP. ADR/2 NEW from 2021 to 2025. See GS70 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €7.74 Billion | €2.98 Billion | ▼ -15.2% |
| 2024 | 0.45x | €6.55 Billion | €2.98 Billion | ▲ +31.4% |
| 2023 | 0.35x | €6.77 Billion | €2.34 Billion | ▲ +13.5% |
| 2022 | 0.31x | €7.40 Billion | €2.26 Billion | ▼ -8.6% |
| 2021 | 0.33x | €7.95 Billion | €2.65 Billion | — |